Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase. Issue 16 (15th August 2015)

• Record Type: Journal Article
• Authors: Visalli, Robert J.; Ziobrowski, Hannah; Badri, Kameswara R.; He, Johnny J.; Zhang, Xiugen; Arumugam, Sri Ranjini; Zhao, Hua
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 25:Issue 16(2015)
• Page Start: 3168
• Page End: 3171
• Publication Date: 2015-08-15
• Subjects: Betulinic acid -- HIV-1 reverse transcriptase -- Herpes simplex type 2 (HSV-2) -- Inhibitor; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2015.05.099
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: New ionic derivatives of betulinic acid (1 ) such as2 and5 show strong inhibition against herpes simplex type 2 (HSV-2) replication with minimal cellular cytotoxicity. Abstract: Betulinic acid (1 ) has been modified to ionic derivatives (2 –5 ) to improve its water solubility and biological activities. The binding properties of these derivatives with respect to human serum albumin (HSA) was examined and found to be similar to current anti-HIV drugs. These compounds did not inhibit HIV reverse transcriptase, however, 1, 2 and5 inhibited herpes simplex type 2 (HSV-2) replication at concentrations similar to those reported for acyclovir (IC50 ∼0.1–10 μM) and with minimal cellular cytotoxicity. IC50 values for antiviral activity against HSV-2 186 were 1.6, 0.6, 0.9, 7.2, and 0.9 μM for compounds1 –5, respectively.